Profile data is unavailable for this security.
About the company
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.
- Revenue in USD (TTM)30.47m
- Net income in USD-170.12m
- Incorporated2005
- Employees117.00
- LocationAnaptysBio Inc10770 WATERIDGE CIRCLE, SUITE 210SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 362-6295
- Fax+1 (858) 362-6296
- Websitehttps://www.anaptysbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cullinan Therapeutics Inc | 0.00 | -142.16m | 1.05bn | 85.00 | -- | 1.60 | -- | -- | -3.10 | -3.10 | 0.00 | 11.34 | 0.00 | -- | -- | 0.00 | -23.96 | -12.37 | -24.85 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
Pharvaris NV | 0.00 | -127.35m | 1.05bn | 82.00 | -- | 2.84 | -- | -- | -2.67 | -2.67 | 0.00 | 6.88 | 0.00 | -- | -- | 0.00 | -42.13 | -36.09 | -45.04 | -38.27 | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | -32.15 | -- | -- | -- |
Vir Biotechnology Inc | 78.88m | -483.04m | 1.06bn | 587.00 | -- | 0.7393 | -- | 13.44 | -3.58 | -3.58 | 0.5838 | 10.50 | 0.0403 | -- | -- | 134,373.10 | -24.69 | -0.6081 | -26.90 | -0.7192 | 98.80 | -- | -612.40 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
Praxis Precision Medicines Inc | 1.77m | -123.74m | 1.09bn | 82.00 | -- | 2.61 | -- | 616.73 | -10.26 | -10.26 | 0.1393 | 23.60 | 0.0062 | -- | -- | 21,597.56 | -43.07 | -74.04 | -46.74 | -85.12 | -- | -- | -6,987.01 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
CARGO Therapeutics Inc | 0.00 | -147.71m | 1.09bn | 116.00 | -- | 2.51 | -- | -- | -3.47 | -3.47 | 0.00 | 9.51 | 0.00 | -- | -- | 0.00 | -53.66 | -- | -59.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
Enliven Therapeutics Inc | 0.00 | -82.83m | 1.10bn | 52.00 | -- | 3.59 | -- | -- | -1.93 | -1.93 | 0.00 | 6.46 | 0.00 | -- | -- | 0.00 | -26.91 | -42.26 | -28.35 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
Phathom Pharmaceuticals Inc | 9.92m | -297.11m | 1.10bn | 452.00 | -- | -- | -- | 110.74 | -5.13 | -5.13 | 0.1717 | -3.99 | 0.0339 | 1.72 | -- | 21,942.48 | -101.68 | -83.26 | -115.19 | -93.77 | 80.15 | -- | -2,995.68 | -135,982.00 | 6.44 | -5.74 | 1.86 | -- | -- | -- | -1.96 | -- | -- | -- |
AnaptysBio Inc | 30.47m | -170.12m | 1.16bn | 117.00 | -- | 106.86 | -- | 38.12 | -6.34 | -6.34 | 1.14 | 0.3601 | 0.0645 | -- | 5.00 | 260,453.00 | -36.02 | -18.08 | -39.45 | -18.96 | -- | -- | -558.25 | -269.21 | -- | -- | 0.00 | -- | 66.78 | 27.97 | -27.11 | -- | -5.36 | -- |
Prothena Corporation PLC | 217.25m | -50.92m | 1.16bn | 173.00 | -- | 2.00 | -- | 5.35 | -1.01 | -1.01 | 3.94 | 10.82 | 0.318 | -- | 829.18 | 1,255,757.00 | -7.45 | -14.20 | -8.16 | -15.11 | -- | -- | -23.44 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
Travere Therapeutics Inc | 177.64m | -383.45m | 1.16bn | 380.00 | -- | 76.77 | -- | 6.55 | -4.99 | -1.88 | 2.31 | 0.1981 | 0.2759 | 0.7613 | 7.92 | 467,484.20 | -59.56 | -36.95 | -74.41 | -44.77 | 94.70 | 95.92 | -215.85 | -165.79 | 2.99 | -- | 0.9615 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
Arcutis Biotherapeutics Inc | 132.06m | -198.76m | 1.19bn | 296.00 | -- | 6.34 | -- | 8.98 | -2.18 | -2.18 | 1.36 | 1.60 | 0.3451 | 0.8334 | 4.36 | 446,155.40 | -51.93 | -65.64 | -58.68 | -71.72 | 92.32 | -- | -150.51 | -1,513.03 | 8.19 | -5.94 | 0.5223 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
Cogent Biosciences Inc | 0.00 | -227.05m | 1.20bn | 164.00 | -- | 4.63 | -- | -- | -2.48 | -2.48 | 0.00 | 3.41 | 0.00 | -- | -- | 0.00 | -55.22 | -49.53 | -60.02 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
Relay Therapeutics Inc | 35.21m | -322.83m | 1.21bn | 304.00 | -- | 1.47 | -- | 34.49 | -2.52 | -2.52 | 0.277 | 5.11 | 0.0406 | -- | -- | 109,003.10 | -37.22 | -28.55 | -39.91 | -29.54 | -- | -- | -916.92 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
Tyra Biosciences Inc | 0.00 | -80.88m | 1.29bn | 49.00 | -- | 3.42 | -- | -- | -1.69 | -1.69 | 0.00 | 7.13 | 0.00 | -- | -- | 0.00 | -25.18 | -- | -25.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
EcoR1 Capital, LLCas of 31 Mar 2024 | 7.52m | 27.53% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.49m | 5.44% |
Tang Capital Management LLCas of 31 Mar 2024 | 1.33m | 4.87% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 1.31m | 4.80% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.21m | 4.42% |
Great Point Partners LLCas of 31 Mar 2024 | 976.98k | 3.58% |
First Light Asset Management LLCas of 31 Mar 2024 | 944.11k | 3.46% |
Point72 Asset Management LPas of 31 Mar 2024 | 864.10k | 3.16% |
Palo Alto Investors LPas of 31 Mar 2024 | 799.91k | 2.93% |
Mangrove Partnersas of 31 Mar 2024 | 689.52k | 2.52% |